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BI1
ADHERENCE AND RESOURCE USE AMONG PATIENTS TREATED wITH 
BIOLOGICS. FINDINGS FROM THE BEETLE STUDy (BIOLOGICAL DRUGS: 
EvALUATION OF ECONOMICS, TREATMENTS, AND LABELING IN REAL-wORLD 
SETTING)
Degli Esposti L., Sangiorgi D., Buda S.
CliCon Srl, Ravenna, Italy
Objectives: Systemic administration of anti-TNF alpha leads to an anti-inflamma-
tory and joint protective effect in pathologies such as rheumatoid arthritis, psoriasis, 
Crohn’s disease. The aim of this study was to assess adherence to therapy and stay 
on treatment (no switches or interruptions) of patients treated with biologics accord-
ing to therapeutic indication and to calculate health care resources consumption 
(drugs, outpatient services, hospitalizations). MethOds: An observational retrospec-
tive cohort analysis based on 5 Local Health Units administrative databases was 
conducted. Patients who filled at least one prescription for anti-TNF alpha between 
January 1, 2009-December 31, 2011 were included. Patients were followed-up for one 
year. Patients were defined as adherent if they had > 80% of follow up period covered 
by drugs dispensation. Results: A total of 1219 patients were analyzed, 47% male, 
age 49.6±14.6. Patients affected by rheumatoid arthritis were 36%, psoriasis 31%, 
Crohn’s disease 10%, psoriatic arthritis 7%, ulcerative colitis 3%, ankylosing spon-
dylitis 3%, diagnosis not available 11%; 420 (34%) were treated with Adalimumab, 
615 (50%) Etanercept, 184 (15%) Infliximab. Among the 94% of patients who did not 
switch, patients treated with Infliximab seemed to have the highest rate of adherent 
patients across all indications: 51%, vs. 27% Etanercept and 23% Adalimumab; at the 
multivariable logistic regression model, Infliximab resulted a protective predictor 
of non adherence for all indications (OR ranged from 0.08 to 0.43). For patients who 
started a first-line biological drug, stay on treatment was 73% for Infliximab, 67% 
Etanercept, 64% Adalimumab. The mean annual expenditure for each patient in analy-
sis was € 11,120; in particular, non-pharmacological expenditure was € 988 for adherent 
and € 1,255 for non-adherent patients; at the multivariable generalized linear model, 
Infliximab was associated with the lowest cost for all indications. cOnclusiOns: 
Patients treated with Infliximab were associated to higher adherence and stay on 
treatment and lower costs, as compared to Adalimumab and Etanercept.
BI2
wHAT ARE THE KEy DRIvERS OF REIMBURSEMENT FOR BIOSIMILARS? AN 
ExAMINATION OF REIMBURSEMENT PROCESSES AND RECOMMENDATIONS 
ACROSS NINE COUNTRIES
de Silva S.U., Smith T.A., Bending M.W.
Mapi, London, UK
Objectives: Biosimilars are biotherapeutic products that are similar in terms of 
quality, safety and efficacy to an already licensed reference biotherapeutic product. 
The first biosimilar (Omnitrope) received EU regulatory approval in 2006; since then, 
14 biosimilars have received marketing authorisation. This study examined the dif-
ferences in the approaches to reimbursement of biosimilars in countries using HTA 
to inform decision-making. MethOds: Four biosimilar medicines were selected to 
provide sufficient documentation in seven European countries, South Korea and 
Australia. Regulatory approval and HTA reimbursement decision documents were 
identified and a qualitative analysis of the processes, recommendations by indica-
tion, evidence and key decision drivers was undertaken to explain differences in 
recommendations across countries. Results: Twenty-one different indications 
were appraised; 90% of appraisals were ‘recommended’, 9% ‘recommended with 
restrictions’, and 1% were ‘not recommended’. The Netherlands and Germany 
accepted ‘clinical comparability’ to the originator as sufficient evidence for auto-
matic reimbursement. Sweden and France were the only countries to appraise and 
to recommend for all indications. Scotland and Wales recommended all biosimilars 
but restricted indications in some cases. Agencies accepted the notion of clinical 
comparability and extrapolation across indications when appraising the evidence. A 
cost-minimisation analysis and budget impact analysis were key economic decision 
drivers. A full cost-effectiveness analysis was only requested by NICE. Other factors 
influential in recommending reimbursement were: lobbying, dual reimbursement 
processes, and other reimbursement mechanisms. cOnclusiOns: As the market 
for biosimilars continues to grow, it is imperative that specific HTA reimbursement 
processes are developed for assessing biosimilars. This includes further research 
on how different drug classes should be considered; especially pertinent due to the 
increase in biosimilars for monoclonal antibody-based drugs, which differ from the 
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product classes (erythropoietin, white blood cell stimulators, growth hormone and 
insulins) currently dominating the market.
BI3
DIFFERENCES IN APPROACH TO BIOSIMILARS: NICE vERSUS SMC 
RECOMMENDATIONS
Izmirlieva M., Ando G.
IHS, London, UK
Objectives: Several biosimilar products have been approved for marketing in the 
European Union, but their market penetration remains slow. Lack of clear reimburse-
ment guidance could be one of the reasons for this slow penetration. This study exam-
ines how many, if any, biosimilar products have been assessed in the UK by NICE and 
by the SMC and to what extent recommendations by the two HTA organisations are 
consistent. MethOds: Secondary research was conducted, including a review of all 
NICE and SMC final guidance and of guidance in progress by NICE to compare the HTA 
process outcome and issues raised by the two HTA agencies. Results: NICE has issued 
only one final guidance for a biosimilar product (Omnitrope) and has another guid-
ance in progress (for epoetin including biosimilars). The SMC has issued guidance for 
4 biosimilar versions of filgrastim (Ratiograstim, TevaGrastim, Zarzio and Nivestim), 
2 biosimilar versions of epoetin (Binocrit and Retacrit) and 1 version of somatropin 
(Omnitrope). All SMC guidance for biosimilars issued to date has been positive. The 
NICE guidance for Omnitrope is positive despite some reservations about the economic 
model. cOnclusiOns: Considering the limited overlap between NICE and SMC deci-
sions (only one drug - Omnitrope - was considered by both agencies), it is difficult to 
assess consistency in the SMC approach compared to NICE’s approach at this stage. 
Based on the biosimilars HTA guidance by NICE and the SMC to date, a cost-minimisa-
tion analysis may be acceptable for biosimilars even if such an approach - in the absence 
of a full cost-effectiveness model - might be rejected for an originator product. Both HTA 
agencies recommend that prescribing for biosimilars should be by brand name to avoid 
automatic substitution in the pharmacy.
BI4
IMPACT OF ExCLUSIvE HOSPITAL DISTRIBUTION OF BIOSIMILAR ON DRUG 
HEALTH CARE BUDGET
Rémuzat C.1, Vataire A.L.2, Cetinsoy L.2, Aballea S.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, PARIS, France, 3University Claude Bernard  
Lyon 1, Lyon, France
Objectives: There is an increased trend in shifting biologics distribution to exclu-
sive hospital pharmacy channel. Although it looks obvious that such process will 
generate savings through tenders at regional or national level such policy conse-
quences were not clearly quantified. We used a model developed for EU commission 
to assess the consequences of such policies on biosimilars for selected EU countries 
(model developed for the European Commission for the project”EU Pharmaceutical 
expenditure forecast” http://ec.europa.eu/health/healthcare/key_documents/index.
en.htm). MethOds: We built a model to assess policy scenarios impact on pharma-
ceuticals reference forecast for seven EU Member States (France, the UK, Germany, 
Poland, Portugal, Greece and Hungary). We tested the impact of shifting biosimilar 
distribution to hospital channel on pharmaceutical industry revenue, Health insurers 
budget and society cost. Results: For the period 2012-2016 the savings of biosimilars 
(based in million Euros) for Health insurance will be for: UK 2,023; GE 1,127; FR 1,634; PL 
200; GR 19; PO 272; HU 29. The extra savings by shifting of the biosimilars distribution 
to exclusive hospital pharmacy will be: for UK 353; GE 3,392; FR 1,684; PL 37; GR 206; PO 
65; HU 176. The difference is relatively small for UK, although significant. However, it is 
considerable for Germany and France (around 3 and 2 time original saving). Similar fig-
ures (revenue loss) are seen for pharmaceutical companies. cOnclusiOns: Although 
the impact of such policy varies from one country to one another based on initial pro-
portion of biosimilar distributed through hospital and level of discount over branded 
products, this policy appears to have a substantial impact on drug expenditures and 
might contribute to sustainability of health insurance in EU countries. Germany and 
France might benefit dramatically from such policy.
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CA1
RESPONSIvENESS OF THE EQ-5D IN ONCOLOGy: A META-ANALySIS
Smith A.B.1, Cocks K.1, Taylor M.2, Parry D.3
1University of York, York, UK, 2York Health Economics Consortium, York, UK, 3AstraZeneca UK, 
Macclesfield, UK
Objectives: The EQ-5D is often employed in clinical trials to derive quality-
adjusted life years for cost-utility analyses, and in comparisons of health-related 
quality of life across conditions. However, there are concerns that the EQ-5D is less 
